|
1
|
Whiting DR, Guariguata L, Weil C and Shaw
J: IDF diabetes atlas: Global estimates of the prevalence of
diabetes for 2011 and 2030. Diabetes Res Clin Pract. 94:311–321.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahelic D: 7th edition of IDF Diabetes
Atlas-call for Immediate Action. Lijec Vjesn. 138:57–58. 2016.(In
Croatian). PubMed/NCBI
|
|
3
|
Shah BR and Hux JE: Quantifying the risk
of infectious diseases for people with diabetes. Diabetes Care.
26:510–513. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Muller LM, Gorter KJ, Hak E, Goudzwaard
WL, Schellevis FG, Hoepelman AI and Rutten GE: Increased risk of
common infections in patients with type 1 and type 2 diabetes
mellitus. Clin Infect Dis. 41:281–288. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Korbel L and Spencer JD: Diabetes mellitus
and infection: An evaluation of hospital utilization and management
costs in the United States. J Diabetes Complicat. 29:192–195. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hine JL, de Lusignan S, Burleigh D,
Pathirannehelage S, McGovern A, Gatenby P, Jones S, Jiang D,
Williams J, Elliot AJ, et al: Association between glycaemic control
and common infections in people with Type 2 diabetes: A cohort
study. Diabetic Med. 34:551–557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Florio W, Morici P, Ghelardi E, Barnini S
and Lupetti A: Recent advances in the microbiological diagnosis of
bloodstream infections. Crit Rev Microbiol. 44:351–370. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vashist SK, Venkatesh AG, Marion Schneider
E, Beaudoin C, Luppa PB and Luong JH: Bioanalytical advances in
assays for C-reactive protein. Biotechnol Adv. 34:272–290. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Muller B and Becker KL: Procalcitonin: How
a hormone became a marker and mediator of sepsis. Swiss Med Wkly.
131:595–602. 2001.PubMed/NCBI
|
|
10
|
Karzai W, Oberhoffer M, Meier-Hellmann A
and Reinhart K: Procalcitonin-a new indicator of the systemic
response to severe infections. Infect. 25:329–334. 1997. View Article : Google Scholar
|
|
11
|
Snider RH Jr, Nylen ES and Becker KL:
Procalcitonin and its component peptides in systemic inflammation:
immunochemical characterization. J Invest Med. 45:552–560.
1997.
|
|
12
|
Alberti KG and Zimmet PZ: Definition,
diagnosis and classification of diabetes mellitus and its
complications. Part 1: Diagnosis and classification of diabetes
mellitus provisional report of a WHO consultation. Diabet Med.
15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Levy MM, Fink MP, Marshall JC, Abraham E,
Angus D, Cook D, Cohen J, Opal SM, Vincent JL and Ramsay G: 2001
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions
Conference. Intensive Care Med. 29:530–538. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wellen KE and Hotamisligil GS:
Inflammation, stress, and diabetes. J Clin Invest. 115:1111–1119.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jafar N, Edriss H and Nugent K: The effect
of short-term hyperglycemia on the innate immune system. Am J Med
Sci. 351:201–211. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barrett EJ, Liu Z, Khamaisi M, King GL,
Klein R, Klein BEK, Hughes TM, Craft S, Freedman BI, Bowden DW, et
al: Diabetic Microvascular Disease: An Endocrine Society Scientific
Statement. J Clin Endocrinol Metab. 102:4343–4410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stegenga ME, van der Crabben SN, Blumer
RM, Levi M, Meijers JC, Serlie MJ, Tanck MW, Sauerwein HP and van
der Poll T: Hyperglycemia enhances coagulation and reduces
neutrophil degranulation, whereas hyperinsulinemia inhibits
fibrinolysis during human endotoxemia. Blood. 112:82–89. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morigi M, Angioletti S, Imberti B,
Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C and
Remuzzi G: Leukocyte- endothelial interaction is augmented by high
glucose concentrations and hyperglycemia in a NF-κB-dependent
fashion. J Clin Invest. 101:1905–1915. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cohen G, Ilic D, Raupachova J and Horl WH:
Resistin inhibits essential functions of polymorphonuclear
leukocytes. J Immunol. 181:3761–3768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Becker KL, Nylen ES, White JC, Muller B
and Snider RH Jr: Clinical review 167: Procalcitonin and the
calcitonin gene family of peptides in inflammation, infection, and
sepsis: A journey from calcitonin back to its precursors. J Clin
Endocrinol Metab. 89:1512–1525. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abbasi A, Corpeleijn E, Postmus D,
Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP,
Navis G and Bakker SJ: Plasma procalcitonin is associated with
obesity, insulin resistance, and the metabolic syndrome. J Clin
Endocrinol Metab. 95:E26–E31. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
James MT, Quan H, Tonelli M, Manns BJ,
Faris P, Laupland KB and Hemmelgarn BR: CKD and risk of
hospitalization and death with pneumonia. Am J Kidney Dis.
54:24–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
James MT, Laupland KB, Tonelli M, Manns
BJ, Culleton BF and Hemmelgarn BR: Risk of bloodstream infection in
patients with chronic kidney disease not treated with dialysis.
Arch Inter Med. 168:2333–2339. 2008. View Article : Google Scholar
|
|
24
|
Davenport A: Peritonitis remains the major
clinical complication of peritoneal dialysis: The London, UK,
peritonitis audit 2002–2003. Perit Dial Int. 29:297–302.
2009.PubMed/NCBI
|
|
25
|
Mactier R: Peritonitis is still the
achilles' heel of peritoneal dialysis. Perit Dial Int. 29:262–266.
2009.PubMed/NCBI
|
|
26
|
Azoulay E, Chevret S, Didier J, Barboteu
M, Bornstain C, Darmon M, Le Gall JR, Vexiau P and Schlemmer B:
Infection as a trigger of diabetic ketoacidosis in intensive
care-unit patients. Clin Infect Dis. 32:30–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Joshi N, Caputo GM, Weitekamp MR and
Karchmer AW: Infections in patients with diabetes mellitus. New
Engl J Med. 341:1906–1912. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marrie TJ: Bacteraemic pneumococcal
pneumonia: A continuously evolving disease. J Infect. 24:247–255.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nichols GA, Brodovicz KG, Kimes TM,
Deruaz-Luyet A and Bartels DB: Prevalence and incidence of urinary
tract and genital infections among patients with and without type 2
diabetes. J Diabetes Complications. 31:1587–1591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luzzani A, Polati E, Dorizzi R,
Rungatscher A, Pavan R and Merlini A: Comparison of procalcitonin
and C-reactive protein as markers of sepsis. Crit Care Med.
31:1737–1741. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Castelli GP, Pognani C, Meisner M, Stuani
A, Bellomi D and Sgarbi L: Procalcitonin and C-reactive protein
during systemic inflammatory response syndrome, sepsis and organ
dysfunction. Crit Care. 8:R234–R242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schuetz P, Albrich W, Christ-Crain M,
Chastre J and Mueller B: Procalcitonin for guidance of antibiotic
therapy. Expert Rev Anti Infect Ther. 8:575–587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee SH, Chan RC, Wu JY, Chen HW, Chang SS
and Lee CC: Diagnostic value of procalcitonin for bacterial
infection in elderly patients-a systemic review and meta-analysis.
Int J Clin Pract. 67:1350–1357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park JH, Kim DH, Jang HR, Kim MJ, Jung SH,
Lee JE, Huh W, Kim YG, Kim DJ and Oh HY: Clinical relevance of
procalcitonin and C-reactive protein as infection markers in renal
impairment: A cross-sectional study. Crit Care. 18:6402014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brechot N, Hekimian G, Chastre J and Luyt
CE: Procalcitonin to guide antibiotic therapy in the ICU. Int J
Antimicrob Agents. 46:S19–S24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tan BH, Png ME, Yeo CP and Wong GC:
Procalcitonin in febrile neutropenia-timing is important. Support
Care Cancer. 22:583–584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bodmann KF, Schenker M, Heinlein W and
Wilke MH: Procalcitonin as a tool for the assessment of successful
therapy of severe sepsis: An analysis using clinical routine data.
Med Klin Intensivmed Notfmed. 113:533–541. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Davies J: Procalcitonin. J Clin Pathol.
68:675–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Claeys R, Vinken S, Spapen H, ver Elst K,
Decochez K, Huyghens L and Gorus FK: Plasma procalcitonin and
C-reactive protein in acute septic shock: Clinical and biological
correlates. Crit Care Med. 30:757–762. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sierra R, Rello J, Bailen MA, Benitez E,
Gordillo A, Leon C and Pedraza S: C-reactive protein used as an
early indicator of infection in patients with systemic inflammatory
response syndrome. Intens Care Med. 30:2038–2045. 2004. View Article : Google Scholar
|
